JPRN-jRCT2031220484招募中2 期
ivolumab, Chemoradiotherapy, and Surgery-2 - VOLTAGE-2
Bando Hideaki0 个研究点目标入组 55 人开始时间: 2022年12月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Histopathologically diagnosed adenocarcinoma.
- •2. Rectal cancer with the inferior margin of the tumor within 12 cm of the anal verge (AV).
- •3. deficient mismatch repair (dMMR/MSI-H) on examination of tissue or blood specimen.
- •4. Age >18 years at the time of enrollment.
- •5. Clinical stage II/III (T3-4 N-any M0, T1-2N1-2M0) in the primary analysis part. In the exploratory part, the clinical stage is Stage I (T1-2 N0 M0), which cannot be cured by endoscopic or local resection.
- •6. Patients with considered to be amenable of radical resection by diagnostic imaging.
- •7. Patient's written informed consent has been obtained.
- •8. Patients with an ECOG Performance Status (PS) of 0 or 1 at the time of enrollment.
- •9. No history of radiation to the pelvic region.
- •10. Women with childbearing potential (including patients who are not menstruating for medical reasons, such as chemical menopause) must have dual contraceptive coverage from the time of consent for at least 5 months after the last dose of nivolumab (or during chemoradiotherapy and for at least 7 months after the last dose of capecitabine, if chemoradiotherapy is administered) Patients who have consented to double contraception and restricted egg donation (including the harvesting of eggs for their own use) for at least 5 months after the last dose of nivolumab. Patients who also agree not to breastfeed from the time consent is obtained for at least 5 months after the last dose of nivolumab (or during chemoradiotherapy and for at least 7 months after the last dose of capecitabine if chemoradiotherapy is administered).
- •11. Men who, if receiving chemoradiotherapy, will use appropriate contraception as specified in this trial during chemoradiotherapy and for at least 7 months after the last dose of capecitabine. And patients who agree not to cryopreserve or donate sperm.
- •12. Patients with adequate organ function at the time of enrollment.
排除标准
- •1.Patients diagnosed with active multiple cancers (concurrent multiple cancers and multiple cancers with a disease-free interval of 5 years or less from the time of enrollment).
- •However, active duplications do not include intraepithelial or intramucosal carcinomas that are considered curable with local treatment. Patients with duplicate cancer of the colon or rectum are eligible if there is no distant metastasis and all lesions are considered surgically resectable.
- •2.Patients with a history of inflammatory bowel disease.
- •3.Patients with a history of pneumonia or interstitial lung disease (ILD).
- •4.Patients with concomitant autoimmune disease or a history of chronic or recurrent autoimmune disease.
- •5.Patients who require systemic corticosteroids (except for prophylactic administration for laboratory or allergic reactions or temporary use to reduce edema associated with radiation therapy) or immunosuppressive agents, or who have received such treatment within 14 days prior to enrollment in this study.
- •6.Patients with a history or findings of cardiovascular risk.
- •7.Patients with poorly controlled diabetes mellitus or other conditions that may interfere with toxicity assessment.
- •8.Patients with positive HIV-1 and HIV-2 antibody tests, HTLV-1 antibody test, HBs antigen test or HCV antibody test. Patients with a negative HBs antigen test but a positive HBs antibody test or HBc antibody test and an HBV-DNA quantitative test with a detection sensitivity of greater than or equal to 0.05. Patients with a negative HBs antigen test but a positive HBs antibody test or HBc antibody test. If the HCV antibody test is positive but the HCV-RNA is negative, enrollment is acceptable.
- •9.Pregnant, lactating, or possibly pregnant patients.
- •10.Patients suffering from a serious or unstable psychiatric or other medical condition that may interfere with the safety of the subject, the obtaining of consent, or compliance with study procedures.
- •11.Patients with a history of prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or other antibody or drug therapies for T-cell control.
- •12.Patients who have received live or attenuated vaccination within 28 days prior to enrollment in this study.
- •13.Patients who are unwilling or unable to comply with the procedures specified in the study protocol.
- •14.Patients who are judged by the investigator to be unsuitable for the clinical trial.
研究者
相似试验
进行中（未招募）
1 期
An investigational immunotherapy study of Nivolumab combined with chemoradiotherapy , compared to chemoradiotherapy by itself, in patients with bladder cancer, not undergoing cystectomymuscle-invasive bladder cancer (MIBC)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003447-34-GRHellenic Genitourinary Cancer Group (HGUCG)78
已完成
1 期
ivolumab and chemoradiotherapy for esophageal cancerJPRN-jRCT1091220408Manabu Muto60
进行中（未招募）
1 期
Does adding double immunotherapy to the combination of chemotherapy and radiotherapy result in a better anti-tumor efficacy?locally advanced non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003454-83-NLAmsterdam UMC, VU University Medical Center29
已完成
2 期
Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLClung carcinoma1003866610029107lung cancerNL-OMON48462Vrije Universiteit Medisch Centrum29
进行中（未招募）
1 期
ivolumab with chemotherapy in pleural mesothelioma after surgeryMedDRA version: 20.0Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Malignant Pleural MesotheliomaEUCTR2019-002466-13-DEInstitut für Klinische Krebsforschung IKF GmbH92